ABEO logo

ABEO
Abeona Therapeutics Inc

11,016
Mkt Cap
$274.98M
Volume
669,948.00
52W High
$7.54
52W Low
$3.93
PE Ratio
4.83
ABEO Fundamentals
Price
$4.79
Prev Close
$4.82
Open
$4.88
50D MA
$4.93
Beta
0.67
Avg. Volume
1.49M
EPS (Annual)
$1.01
P/B
1.67
Rev/Employee
$25,752.21
$182.10
Loading...
Loading...
News
all
press releases
HC Wainwright Issues Pessimistic Outlook for ABEO Earnings
Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2026 EPS estimates for Abeona Therapeutics in a report released on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post ear...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday...
MarketBeat·18d ago
News Placeholder
Abeona Therapeutics Q4 Earnings Call Highlights
Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric...
MarketBeat·20d ago
News Placeholder
Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts' consensus...
MarketBeat·20d ago
News Placeholder
Abeona Therapeutics Inc. $ABEO Shares Sold by Boone Capital Management LLC
Boone Capital Management LLC decreased its holdings in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 59.9% during the third quarter, according to its most recent disclosure with...
MarketBeat·22d ago
News Placeholder
Q4 EPS Forecast for Abeona Therapeutics Increased by Analyst
Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Stock analysts at HC Wainwright boosted their Q4 2025 EPS estimates for shares of Abeona Therapeutics in a research note issued on Tuesday...
MarketBeat·25d ago
News Placeholder
Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026
Abeona Therapeutics (NASDAQ:ABEO) executives said the commercial launch of ZEVASKYN is gaining momentum after an early manufacturing-related delay, outlining progress on treatment center activation...
MarketBeat·27d ago
News Placeholder
HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO)
HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday...
MarketBeat·27d ago
News Placeholder
Abeona Therapeutics (ABEO) Projected to Post Earnings on Tuesday
Abeona Therapeutics (NASDAQ:ABEO) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...
MarketBeat·28d ago
News Placeholder
Abeona Therapeutics Inc. $ABEO Shares Sold by Western Standard LLC
Western Standard LLC lowered its holdings in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 40.2% during the third quarter, according to the company in its most recent filing with the SEC...
MarketBeat·1mo ago
<
1
2
...
>

Latest ABEO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.